Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Attention Deficit Disorder with Hyperactivity | 9 | 2020 | 248 | 2.190 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 2022 | 92 | 1.420 |
Why?
|
| Mental Disorders | 3 | 2025 | 910 | 0.970 |
Why?
|
| Methylphenidate | 2 | 2015 | 58 | 0.800 |
Why?
|
| Epilepsy | 2 | 2021 | 876 | 0.800 |
Why?
|
| Receptors, Peptide | 2 | 2020 | 60 | 0.590 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2020 | 289 | 0.510 |
Why?
|
| Glutamate Decarboxylase | 1 | 2016 | 45 | 0.480 |
Why?
|
| Central Nervous System Stimulants | 1 | 2015 | 133 | 0.410 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2012 | 16 | 0.370 |
Why?
|
| Appetite | 1 | 2012 | 35 | 0.360 |
Why?
|
| Sclerosis | 2 | 2021 | 31 | 0.340 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 2833 | 0.330 |
Why?
|
| Hippocampus | 3 | 2022 | 806 | 0.260 |
Why?
|
| Genetic Association Studies | 4 | 2020 | 819 | 0.260 |
Why?
|
| Polymorphism, Genetic | 3 | 2016 | 776 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2025 | 3436 | 0.240 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2016 | 28 | 0.230 |
Why?
|
| Caribbean Region | 1 | 2025 | 20 | 0.220 |
Why?
|
| Latin America | 1 | 2025 | 110 | 0.220 |
Why?
|
| Genome-Wide Association Study | 3 | 2025 | 1833 | 0.210 |
Why?
|
| Alleles | 3 | 2016 | 1673 | 0.170 |
Why?
|
| Genotype | 5 | 2016 | 2595 | 0.150 |
Why?
|
| Humans | 15 | 2025 | 131163 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2025 | 1559 | 0.140 |
Why?
|
| Child | 6 | 2020 | 26341 | 0.130 |
Why?
|
| Adult | 5 | 2021 | 31282 | 0.130 |
Why?
|
| Genomics | 1 | 2025 | 1621 | 0.120 |
Why?
|
| Proteostasis Deficiencies | 1 | 2016 | 5 | 0.120 |
Why?
|
| Hyperkinesis | 1 | 2016 | 26 | 0.120 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2016 | 10 | 0.120 |
Why?
|
| Adolescent | 6 | 2016 | 20987 | 0.110 |
Why?
|
| Impulsive Behavior | 1 | 2016 | 161 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2015 | 87 | 0.110 |
Why?
|
| Haplotypes | 1 | 2016 | 519 | 0.110 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2014 | 47 | 0.110 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 138 | 0.100 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 96 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 248 | 0.100 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2013 | 16 | 0.100 |
Why?
|
| Memory Disorders | 1 | 2015 | 204 | 0.100 |
Why?
|
| PPAR alpha | 1 | 2013 | 54 | 0.100 |
Why?
|
| Gene-Environment Interaction | 1 | 2014 | 127 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 201 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 3763 | 0.090 |
Why?
|
| Receptors, Steroid | 1 | 2013 | 167 | 0.090 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2012 | 8 | 0.090 |
Why?
|
| Acetylation | 1 | 2012 | 190 | 0.090 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 318 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 239 | 0.080 |
Why?
|
| Neuroimaging | 1 | 2014 | 385 | 0.080 |
Why?
|
| Homozygote | 1 | 2012 | 533 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2013 | 256 | 0.080 |
Why?
|
| Aging | 1 | 2016 | 1242 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3359 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 3061 | 0.070 |
Why?
|
| Male | 6 | 2016 | 64957 | 0.070 |
Why?
|
| Female | 6 | 2016 | 70963 | 0.060 |
Why?
|
| Risk Factors | 2 | 2016 | 11074 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2550 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 70 | 0.030 |
Why?
|
| Transcriptome | 1 | 2022 | 1103 | 0.030 |
Why?
|
| Intelligence Tests | 1 | 2015 | 62 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 423 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 928 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 79 | 0.020 |
Why?
|
| Simvastatin | 1 | 2013 | 76 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2016 | 324 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 350 | 0.020 |
Why?
|
| HapMap Project | 1 | 2012 | 13 | 0.020 |
Why?
|
| Pyrroles | 1 | 2013 | 188 | 0.020 |
Why?
|
| Brazil | 1 | 2012 | 116 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 830 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 960 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2012 | 121 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2012 | 178 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1029 | 0.020 |
Why?
|
| Autism Spectrum Disorder | 1 | 2016 | 450 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 1447 | 0.020 |
Why?
|
| Lipids | 1 | 2013 | 569 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2825 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2304 | 0.010 |
Why?
|
| Middle Aged | 2 | 2016 | 28601 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 6797 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 4497 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 10103 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2015 | 15110 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 12936 | 0.010 |
Why?
|
| Aged | 1 | 2013 | 21025 | 0.010 |
Why?
|